Junshi and Lilly to develop and commercialize antibodies for prevention and treatment of COVID-19 coronavirus
Clients Shanghai Junshi Biosciences Co., Ltd.
Jones Day represented Shanghai Junshi Biosciences Co., Ltd. in its strategic collaboration and license agreement with Eli Lilly and Company for the development, manufacturing, and commercialization of two antibodies for the prevention and treatment of the COVID-19 SARS-CoV-2 novel coronavirus. Junshi and Lilly will collaborate to conduct clinical trials using antibodies controlled by Junshi and licensed to Junshi from a research institute in China and sublicensed to Lilly. Lilly will conduct trials and commercialization outside of Greater China and Junshi will do so within Greater China.